Question explored with the scientific record
when supplementing T4 & T3 for hashimotos, is it a concern that tsh is very low?
A very low TSH on T4+T3 for Hashimoto’s is a red flag for overtreatment, not a goal.
The evidence retrieved does not directly study Hashimoto’s patients on combination T4+T3 therapy. That gap matters. What exists comes from thyroid cancer patients on TSH-suppressive therapy, a different population with a different goal. In that group, suppressed TSH (≤0.4 mU/L) carried a 3.5-fold higher risk of osteoporosis in women, with no reduction in cancer recurrence versus non-suppressed patients [4]. Atrial fibrillation appeared in 2.3% of the suppressed group [4]. Long-term suppression also shifted metabolism, lowering T3 and T4 over years [7], and was linked to increased pericardial fat in postmenopausal women [10].
The 2008 BMJ guidance for hypothyroidism targets TSH in the lower half of the reference range, roughly 0.4–2.5 mU/L, and explicitly says combination T4+T3 offers no clear benefit over T4 alone [1]. A suppressed TSH below that range is not the target. It signals you are taking more hormone than your body needs, and the risks are bone loss and heart rhythm problems, not theoretical ones.
| Group | TSH level | Key risk |
|---|---|---|
| Suppressed (cancer pts) | ≤0.4 mU/L | Osteoporosis HR 3.5; AF 2.3% [4] |
| Target (hypothyroid) | 0.4–2.5 mU/L | Standard goal [1] |
My call: a very low TSH on T4+T3 for Hashimoto’s is a concern and should prompt a dose reduction, not celebration. Confidence: moderate, because the direct evidence in Hashimoto’s patients on combination therapy is absent, and the harms are extrapolated from thyroid cancer cohorts.
Sources examined 15
-
Management of hypothyroidism in adults
This BMJ article provides evidence-based guidance for the management of hypothyroidism in adults, detailing diagnostic criteria, levothyroxine replacement dosing, monitoring strategies, and special considerations (pregnancy, elderly, and ischemic heart disease), while noting tha…
DOI: 10.1136/bmj.a801 -
T3, the other thyroid hormone
This paper discusses the role of thyroid hormones, particularly T3 and T4, in metabolic processes and presents a case study of a patient with hypothyroidism, exploring treatment options and the implications of combination therapy with levothyroxine and liothyronine.
DOI: 10.1016/s1098-3597(05)80053-5 -
Recurrence of Differentiated Thyroid Carcinoma During Full TSH Suppression: Is the Tumor Now Thyroid Hormone Dependent?
A perspective proposing that in well-differentiated differentiated thyroid carcinoma (DTC) patients who are fully thyrotropin (TSH) suppressed with thyroid hormone, recurrence may be driven by thyroid hormone (T4/T3) signaling at the cell-surface integrin αvβ3, outlining in vitr…
DOI: 10.1007/s12672-014-0204-z -
Thyrotropin Suppression Increases the Risk of Osteoporosis Without Decreasing Recurrence in ATA Low- and Intermediate-Risk Patients with Differentiated Thyroid Carcinoma
This study investigates the effects of TSH suppression on the risk of osteoporosis and tumor recurrence in patients with differentiated thyroid carcinoma classified as low and intermediate risk by the American Thyroid Association, finding that TSH suppression increases the risk …
DOI: 10.1089/thy.2014.0287 -
The Effect of TSH Suppression Therapy on the Efficacy and Immune Function of Postoperative Patients with Thyroid Cancer
TSH suppression therapy after thyroid cancer surgery improves thyroid function, boosts cellular immune markers, and lowers tumor markers Tg and CEA compared with standard hormone replacement.
DOI: 10.26689/par.v7i4.5152 -
Impact of moderate vs stringent TSH suppression on survival in advanced differentiated thyroid carcinoma
This study investigates the impact of moderate versus stringent TSH suppression on survival outcomes in patients with advanced differentiated thyroid carcinoma, revealing that while non-suppressed TSH levels correlate with worse prognosis, further suppression below certain thres…
DOI: 10.1111/j.1365-2265.2011.04272.x -
Changes within the thyroid axis after long‐term TSH‐suppressive levothyroxine therapy
This study investigates the effects of long-term TSH-suppressive levothyroxine therapy on thyroid hormone metabolism in patients with differentiated thyroid carcinoma, revealing significant changes in hormone levels and metabolism over time.
DOI: 10.1111/j.1365-2265.2011.04262.x -
LBSAT312 SARS-CoV-2 MRNA Vaccine Side Effects Or Something More? Case Series - Vaccine Induced Mild, Self-limiting Thyroiditis.
Two healthy women developed transient, self-limiting thyroiditis with suppressed TSH and elevated free T4 within weeks of SARS-CoV-2 mRNA vaccination, followed by resolution with conservative management.
DOI: 10.1210/jendso/bvac150.1544 -
Thyroid cancer, recent advances in diagnosis and therapy
A comprehensive, narrative review of recent advances in diagnosis and therapy for follicular-cell-derived thyroid cancer, highlighting active surveillance for low-risk papillary thyroid cancer, more conservative surgical approaches, reduced use of radioactive iodine, nuanced TSH…
DOI: 10.1002/ijc.33690 -
Change in pericardial fat volume in postmenopausal women with papillary thyroid cancer undergoing thyrotropin suppressive therapy
A retrospective PET/CT-based study in postmenopausal women with papillary thyroid cancer on thyrotropin suppressive therapy showing increased epicardial fat volume over ~2 years, with no significant changes in visceral fat or skeletal muscle, and an independent association betwe…
DOI: 10.1186/s12902-024-01800-4 -
Impact of DIO2 polymorphisms on quality of life and TSH suppression therapy in patients with papillary thyroid cancer
A single-center prospective cohort study evaluating how DIO2 polymorphisms (rs225014 and rs12885300) influence quality of life and TSH-suppressive therapy requirements in papillary thyroid cancer patients, comparing lobectomy versus total thyroidectomy with 131I therapy, and fin…
DOI: 10.1186/s12902-025-02085-x -
Metabolic implications of low-dose triiodothyronine administration in rats: Relevance to the adjunctive use of triiodothyronine in the treatment of depression
In a rat model, chronic low-dose, nonpulsatile triiodothyronine (T3) administration partially suppresses T4 and TSH without markedly elevating T3, resulting in tissue indicators of euthyroidism and no peripheral hypermetabolism, with implications for adjunctive T3 use in depress…
DOI: 10.1016/0006-3223(94)91144-4 -
L-Thyroxine TSH-Suppressive Therapy Does Not Impair Cognitive Function
This study investigates the cognitive effects of long-term L-thyroxine TSH-suppressive therapy in women, finding no impairment in cognitive function despite some decrements in health status and mood.
DOI: 10.1089/ct.2014;26.78-79 -
Weight Changes After Thyroid Surgery for Patients with Benign Thyroid Nodules and Thyroid Cancer: Population-Based Study and Systematic Review and Meta-Analysis
This study investigates weight changes in patients undergoing thyroid surgery for benign thyroid nodules and thyroid cancer, revealing minimal clinically significant weight gain across different patient groups over time.
DOI: 10.1089/thy.2017.0216 -
Comparison of Triiodothyronine Level in Patients Treated with Levothyroxine for Different Causes of Hypothyroidism Farklı Hipotiroidizm Nede
In levothyroxine-treated hypothyroid patients, FT3 levels vary by underlying cause, with Hashimoto-associated cases showing the highest FT3 and those treated with radioiodine showing the lowest, despite normal TSH, suggesting etiology-dependent tissue T3 availability under LT4 m…
DOI: 10.25179/tjem.2019-71845